GUARDANT360™ This test and subsequent analysis to identify biomarkers of tumor of each patient to predict prognosis and evolution, as well as offer options more targeted and personalized treatment.

GUARDANT360™ Uses noninvasive tumor sequencing technique (Guardant Digital Sequencing ™) to sequence a panel of mutations, alterations in the number of copies and rearrangements present in genes directly related to cancer
(clinically actionable mutations).

It is the only noninvasive tumor sequencing using a new technology able to isolate the circulating tumor DNA in blood to identify genomic alterations present in the genomic tumor panel.